Intuitive Surgical (ISRG)

Intuitive Surgical’s first quarter results for 2026 exceeded Wall Street’s expectations, with management crediting the outcome to strong global procedure gro...

These companies offer a clear path to sustained earnings growth.

The healthcare industry is less correlated to macroeconomic forces.

The robots aren't coming in the healthcare sector; they are already here, and Intuitive Surgical sells them.

The surgical robotics company's latest quarterly report was exceptional across the board.

Intuitive Surgical's stellar first-quarter earnings reminded the market why it is a 195-bagger since 2000.

What Happened? Shares of medical technology company Intuitive Surgical (NASDAQ:ISRG) jumped 7.6% in the afternoon session after the company reported strong f...

ISRG Q4 2024 Earnings Transcript

ISRG Q3 2024 Earnings Transcript

Intuitive Surgical (NASDAQ:ISRG) reported strong Q1 results, exceeding revenue and earnings estimates. Analysts adjust price targets.

Medical technology company Intuitive Surgical (NASDAQ:ISRG) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 23% year on year...

ISRG Q1 2026 Earnings Transcript

Medical technology company Intuitive Surgical (NASDAQ:ISRG) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 23% year on...

Intuitive Surgical Inc (NASDAQ:ISRG) reports financial results for the first quarter of 2026 after the market close on Tuesday.

Many surgeries are becoming less invasive, and this company is profiting handsomely from that. You could, too.

Various concerns weighed on appetite for stocks in recent weeks.

Medical technology company Intuitive Surgical (NASDAQ:ISRG) will be reporting earnings this Tuesday afternoon. Here’s what to expect. Intuitive Surgical beat...

Intuitive Surgical has already made many of its early investors wealthy.

Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared "Stelara" patent cliff. The healthcare titan reported an adjusted earnings per share (EPS) of $2.70, comfortably ahead of the $2.66

This surgery stock stands to benefit greatly from demographic change and its impact on healthcare.